see signific deviat consensu across
larg cap coverag expect investor focu
growth opportun capit alloc smid
expect focu gwph
 ep mse revenu vs
con driven mainli prolia rx data somewhat
unseason weak aranesp assum price eros
share shift epogen biosimilar would note taken conserv
assumpt given lack visibl question quarter includ
updat view kra specif combin work molecular sequenc
patient net price view across key product aimovig repatha
biosimilar enbrel management comment current polit
environ potenti legisl impact drug price
uw pt ep mse estim broadli
in-line consensu total revenu question quarter
includ updat view impact zolgensma spinraza updat
pipelin view especi on-go analysi aducanumab
potenti ration alzheim pipelin also look forward
detail time psp management view competit landscap
ms mani new agent could launch next year expect major
move quarter see slightli downsid upsid risk
revenu given management expect sequenti neg impact net price
due larger rebat vs season low
ew pt ep mse in-line total
revenu would highlight sequenti comp unfavor
due one-tim posit rebat revers book
eu hcv hiv hbv ep benefit typic
season lower versu season higher letairi erod
significantli gener launch question quarter
includ focu remain ceo day updat strategi
like grand reveal investor remain focus potenti move
oncolog action take bolster pipelin yescarta
increas could increment impact
continu launch trajectori biktarvi key eu countri
on-line expect major move quarter
ew pt us eylea mse slightli
quarter driven conserv eylea forecast y/i
growth vs last quarter y/i growth expect dupix beat vs
con key product rel in-line question
quarter includ management view novarti beovu label dupix asthma
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
launch outlook growth new indic updat pipelin view
ye catalyst management view way improv
profit across sanofi jv view intern invest see
upsid risk quarter though would expect strateg comment
around sanofi relationship pipelin disproportion impact
versu report
ow pt ow pt expect limit movement
quarter vertex broadli in-line consensu
remain focus data aatd next key catalyst alexion
also broadli in-line consensu expect investor focu
impact nmo launch capit alloc prioriti biomarin
in-line revenu expect recoveri latin america
order pattern hemophilia file vosoritid data remain key
catalyst genmab expect in-line revenu well believ upcom
catalyst bispecif potenti interim analysi
darzalex al amyloidosi remain key driver final
slightli consensu vs given estim remain management
guidanc rang believ investor expect beat rais quarter
would disappoint management rais mid-point sale guidanc
consensu
neurocrin ahead ingrezza sale vs con investor
view bar believ doabl other think
neurocrin need exceed stock work recal
typic season headwind compani report anoth
record number new patient neurocrin continu benefit
sale forc expans ultragenyx slightli crysvita
sale vs con would look updat expect
see expect stock impact well indic
benefit crysvita launch improv access genet test
pedigre analysi slightli cabometyx sale
price increas juli expect wholesal inventori increas sinc
remain low end rang end see
gw pressur late investor concern
growth post initi bolu expect sale like well ahead
number possibl push pass level remind
investor management highli conserv set sale expect
epidiolex quarter sinc launch therapi handili beat
street number earn report alnylam expect onpattro
continu strong launch trajectori potenti exceed
estim continu see onpattro becom domin treatment
hattr-pn irrespect cardio statu initi coverag ascendi
ow rate see ascendi risk reward
gener line consensu expect jakafi tymlo
andexxa respect slightli ahead jakafi sale
vs con expect continu volum growth
advanc phiii gvhd readout expect jakafi second-lin chronic
gvhd itacitinib first-lin acut gvhd would expect
investor focu jakafi uptak progress second-lin acut gvhd
order better understand gvhd opportun also expect investor
look addit granular upcom phiii gvhd readout well
pipelin progress broadli includ pemigatinib regulatori
progress cca phiii program ruxolitinib cream atop dermat
 vitiligo line consensu tymlo
expect investor focu heavili management commentari regard
recent approv forteo competitor cover
potenti implic tymlo see previou note topic
slightli total andexxa vs
consensu although note estim includ small amount
eu sale wherea believ consensu repres sale
believ sentiment expect andexxa go quarter mix
believ andexxa would post sizabl beat vs consensu
order notabl shift on-going debat regard much andexxa sale
act financi advisor bristol-my squibb compani
bristol-my relat propos acquisit celgen corpor
celgen announc januari propos transact subject
customari close condit includ bristol-my celgen stockhold
approv receipt customari close condit regulatori approv
report inform provid herein intend provid vote
advic ii serv endors propos transact iii result
procur withhold revoc proxi action secur
holder bristol-my agre pay fee financi
servic includ transact fee financ fee conting upon
consumm transact pleas refer note end report
act financi advisor bristol-my squibb compani
relat agreement celgen corpor celgen
inc would acquir global right
otezla apremilast announc august transact
pursuant merger agreement celgen propos
transact subject celgen enter consent decre
feder trade commiss connect pend merger close
pend merger satisfact customari close condit
ew pt lower pt updat view
market potenti bcma car-t includ greater competit
adc/bi-specif approach lower probabl signific penetr earlier
line therapi also moder expect around scd launch
penetr us revenu declin
ew pt lower pt better align market
risk premium disproportion impact compani termin valu
make signific portion valuat edita
ow pt lower pt better align market
risk premium disproportion impact compani termin valu
make signific portion valuat evelo also better align
launch timelin given greater visibl across pipelin
ftsv ow pt lower pt management provid clear path
registr md dlbcl indic resourc concentr
two indic ad new market model md adjust dlbcl
penetr light competit landscap updat timelin market
better align management recent updat
ow pt lower pt base adjust
sarepta model updat potenti dmd genetherapi royalti model
also updat time-to-market expect around price wamd
ow pt lower pt better align market
risk premium disproportion impact compani termin valu
make signific portion valuat rubiu
ow pt lower pt remov
golodirsen/casimersen model given uncertainti around fda approv
timelin also move dmd genetherapi launch one year
account longer timelin recent outlin management
nc chang price
valuat methodolog risk associ recommend rate price target referenc report pleas contact client
support follow us/canada hong kong latin america london
singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
stock rate price target estim compani remov consider report applic law and/or
polici may preclud issu inform respect compani time
equal-weight rate base
expect limit upsid near-term
posit luspatercept
assum high probabl approv
next set data
luspatercept phase data beta-th
top-line luspatercept phase data mf
preliminari phase part data
preliminari sotatercept data phase
pulsar studi patient pah
data non-transfus depend beta-th
risk achiev price
upsid risk better-than-expect mf
downsid risk neg mf cmt data
pt deriv dcf use
discount rate assum po rs md transfusion-
depend beta-th addit assum po
first line md non-transfusion-depend beta-th mf
posit data mf non-transfus depend beta-th bull case
assum higher probabl success po non-transfus
depend beta-th mf
luspatercept launch reach peak ww revenu
first two indic base case assumpt describ price
target methodolog
luspatercept launch slower-than-expect bear case assum peak
us market share md beta-th respect
addit assum luspatercept success follow-on indic
vadadustat drive akebia share
vadadustat drive akebia share
pt deriv dcf use discount rate
termin growth rate beyond valu akebia nephrolog
vadadustat exce expect allow therapi take addit share
epo regimen appli risk adjust
vadadustat launch drug profil allow success howev
ampl risk remain program lead risk adjust
vadadustat fail merger fall compani valu cash
equal-weight ahead phiii
major cardiac event mace data
see vadadustat therapi
benefit allow remov black
box respect cardiovascular event
might necessari success versu
roxadustat lead time roxadustat
unabl establish mace non-inferior
dd ndd select
achiev mace read-through
vadadustat mix expect share
face pressur remain
infrastructur auryxia need show us
recent merger keryx
auryxia join vadadustat compani
ckd aresen auryxia
underperform sinc approv
hypophosphatemia though drug
recent expand label includ iron
defici anemia need see
drug perform gain confid
main valuat driver
perceiv clinic regulatori risk
vadadustat ckd dialysi set
risk achiev price
vadadustat demonstr lack efficaci
signific safeti issu emerg lead
program discontinu
roxadustat compet ckd
akebia might need rais addit fund
issu equiti
acquisit lundbeck close
acquisit lundbeck close
potenti us approv eptinezumab
risk achiev price
primari risk acquisit
lundbeck fall
price target base announc acquisit valuat
bid competitor lead increas acquisit price
acquisit close announc
acquisit lundbeck close alder unabl obtain
approv eptinezumab aldr trade cash value-per-share
safeti efficaci data ftd-grn drive risk/reward
safeti efficaci data ftd-grn
pt deriv dcf use discount
rate termin growth rate revenu driver model
current model
separ given earli stage develop
commerci strong uptak bull
case valu product launch
begin respect gener
sale
success commerci base
case valu product launch
begin respect gener
risk-adjust sale
fail unabl commerci trade cash
overweight thesi base
success commerci
design treat well defin
genet diseas measur biomark
compar neurodegen
probabl success
phi trial healthi volunt
demonstr target engag
provid confid impact genet
phib data ftd-pgrn
demonstr safeti efficaci expect
phii data ftd-pgrn patient also
demonstr clinic activ expect
demonstr efficaci
alzheim diseas expect
risk achiev price
signal would like caus investor
question valu
reduc efficaci ftd
delay timelin posit data
competitor could weigh
market share especi competitor data
arriv new indic prior pivot
effect treat
sale
research develop
gener administr
net loss comprehens loss
oper expens
ultomiri share convers soliris/strensiq/kanuma sale growth drive
ultomiri share convers soliris/strensiq/kanuma sale growth drive
overweight believ
current valuat impli manag
unabl grow busi
overlook share shift potenti
ultomiri even conserv scenario
assum ultomiri achiev solid
profil assum either market share
price pressur year
assum strensiq achiev
meaning sale see modest sale
key revenu driver model
continu ahu pnh sale growth
franchis coupl growth
soliri mg success share shift
risk achiev price
soliri pnh ahu mg growth could fail
meet expect
strensiq and/or kanuma fail captur
share convers soliri ultomiri
project
could potenti
question behavior identifi
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu
driver model pnh sale ahu sale mg sale nmo sale
strensiq sale kanuma sale incorpor cash cost
diagnost algorithm drive sustain pnh ahu mg penetr
ultomiri succe signific share convers bull case assum
soliri becom standard care pnh ahu nmo mg pnh
sale peak ww ahu sale peak
assum strensiq kanuma continu launch sale
respect
soliri meaning growth pnh ahu gmg ultomiri succe
modest share convers base case assum solid convers ultomiri
long-term durabl complement franchis assum gmg
nmo meaning contribut sale assum strensiq kanuma
continu launch sale respect
see soliri longev incorpor competit price pressur
soliri face signific competit strensiq kanuma achiev minim
sale bear case assum soliri fail gain label expans soliri
face signific headwind biosimilar proprietari competit
diversif strensiq kanuma minim
onpattro sale advanc pipelin drive valu
onpattro sale advanc pipelin drive valu
pt deriv dcf use discount rate
termin growth rate beyond valu alnylam advanc
attr platform highli success givosiran lumasiran achiev strong sale
fitusiran inclisiran launch bull scenario assum onpattro
follow-on highli success form attr
givosiran lumasiran launch sell well fitusiran inclisiran
abl success gain approv appli modest pipelin valu
drug includ inclisiran cemdisiran
attr franchis drive valu givosiran launch lumasiran launch
onpattro strong launch attr la launch aln-
drive sale model aip revenu givosiran
begin howev risk adjust lumasiran launch
risk adjust appli modest pipelin valu drug
onpattro launch modest sale givosiran launch
onpattro achiev modest sale givosiran launch
overweight alnylam
believ mani risk challeng
alnylam give way
commerci growth expect
investor focu onpattro launch
exceed expect view
expect givosiran launch
lumasiran
view alnylam rnai platform
high potenti valu consid
rnai simpler demonstr
preclin proof concept
technolog alnylam larg pipelin
beyond ttr therapi offer potenti
substanti downstream valu
ramp onpattro well
clinical/regulatori updat
givosiran lumasiran fitusiran inclisiran
drive share
risk achiev price
pipelin failur proprietari
rnai therapi could lead substanti
chang share valu
neg safeti and/or efficaci data
therapeut program
clinic data competit program
suggest disadvantag drug
safeti efficaci data mg itp pv drive risk/reward
safeti efficaci data mg itp pv
pt deriv dcf use
discount rate termin growth rate revenu driver
model
commerci strong uptak bull case
valu risk adjust vari
product launch begin
respect gener sale
argenx success commerci base
case valu mg itp pv aml ctcl risk adjust vari
product launch begin
respect gener sale
fail argenx unabl commerci argx trade
overweight thesi base
success commerci
sever compani develop anti-
fcrn antibodi treatment
autoimmun diseas mani compani
report safeti and/or reduc efficaci
compar
design uniqu ph-
depend bind profil extend
therapeut durabl fewer report
advers event compar compet anti-
diseas indic demonstr
efficaci safeti
demonstr clinic
activ aml
phiii data gmg demonstr
differenti safeti efficaci
phii data pv itp also
top-line phiii data gmg expect
demonstr efficaci aml
risk achiev price
signal would like caus investor
question differenti valu
reduc efficaci
delay timelin posit data
competitor could weight
market share especi competitor data
arriv new indic prior pivot
effect treat
refractori aml patient compar
standard care
transcon hgh launch primari near-term opportun pipelin drive
launch primari near-term opportun pipelin drive
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model transcon hgh pth
deeper penetr transcon hgh pth adopt
transcon commerci product driven differenti risk-benefit profil
trancon hgh strong grower current project launch
therapi risk adjust revenu reach assign
risk adjust given posit phiii data date pediatr larg drive
valuat predict drug gain use adult assum
transcon pth would launch
transcon pth fail launch hgh modest penetr clinic
failur result revenu pth hgh gain modest
transcon hgh could game changer
growth hormon market drug like
approv growth hormon
defici data date show
posit result two phiii studi
nave height trial pre-treat flight
trial patient bla transcon hgh
track submit long act
hgh welcom addit
prescrib patient allow
ascendi ramp quickli project
opportun transcon pth replac
therapi treatment
hypoparathyroid could potenti
establish infus like profil
long-act mechan incorpor
transcon technolog allow drug
address root caus diseas
current model launch transcon
valu manag note
potenti expand growth
disord provid opportun
leverag potenti synergi within
platform plan also made move
oncolog overal mechan
combin benefit prodrug
launch transcon
primari driver ascendi
success pipelin candid increas
investor confid transcon platform
contribut greater overal valu
risk achiev price
clinic failur transcon pth
due lack efficaci emerg safeti
investor lose confid platform
attract lentivir gene therapi platform drive valu
attract lentivir gene therapi platform drive valu
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model risk adjust sale fabri diseas gaucher
diseas market well underli gene therapi platform valu
steeper ramp fabri gaucher scenario assum first revenu avr-rd-
reach peak appli risk adjust
launch reach peak risk
adjust includ modest peak adjust sale pomp cystinosi
fabri gaucher drive valu scenario assum first revenu
reach peak appli risk adjust avr-
launch reach peak risk
program fail valu cash
gene therapi compani
develop lentivir therapi lysosom
compani lead therapi
fabri diseas alreadi clinic data
human suggest therapi
could potenti cur derisk
establish market alreadi identifi
popul also regulatori path well
establish make diseas less riski
rare diseas opportun
program earliest
potenti approv primari driver
valuat gaucher
diseas also key driver
risk achiev price
poor clinic data neg impact
street view specif pipelin
product gene therapi whole would
detriment share valu
lsd establish market
standard care product
like higher bar success
compet technolog gene
competit risk long haul
success develop i/o combin therapi access ex-china market
success develop i/o combin therapi access ex-china market
execut local china market drive risk/reward
execut local china market drive risk/reward
pt deriv dcf use discount rate
termin growth rate beyond valu beigen four clinic
stage product candid recent acquir oper china
beigen four product candid achiev strong uptak china
ex-china market driven differenti profil uniqu
combin therapi product sale reach
beigen
earn royalti ex-china sale revlimid
abraxan vidaza china gener annual sale
beigen abl launch four current clinic stage product
candid modest uptak within outsid china product sale
estim
beigen earn royalti ex-
china sale revlimid abraxan vidaza china
gener annual sale
failur develop launch molecul combin therapi china
overweight beigen preclin
earli clinic data indic beigen four
parp inhibitor could
present differenti profil varieti
beigen uniqu posit develop
i/o combin therapi given own
compon drug preclin studi in-
hous combin promis date
choos develop drug china
beigen elig pursu potenti
acceler path approv
multi-national competitor could provid
year head start access chines
uptak oncolog drug china
indic strong demand healthcar
insur reform grow market
time believ chines market
could serv valuat backstop
beigen deal celgen provid
commerci portfolio china provid
infrastructur help facilit eventu
commerci beigen product
candid china
updat chines penetr
btk parp program
monotherapi combin platform
updat pathway
risk achiev price
on-going clinic trial particularli
inabl demonstr superior
compet compound later-stag
develop market
regulatori chang china
develop posit access
spinraza tecfidera ocrevu pipelin drive risk-reward
spinraza tecfidera ocrevu pipelin drive risk-reward
ocrevu pipelin
tecfidera reach higher market share limit impact biosimilar
signific margin expans lower discount pipelin asset
assum peak tecfidera sale gener
limit declin plegridy/avonex franchis
continu tysabri growth peak sale spinraza sale
limit impact rituxan/gazyva biosimilar
impact assum peak tecfidera sale gener
enter declin plegridy/avonex sale
stabl tysabri sale biosimilar rituxan impact
start mainli off-set grow ocrevu royalti
impact pipelin assum global tecfidera sale
loss patent protect declin plegridy/avonex sale
greater competit signific neg price
environ biosimilar rituxan impact start
uw rate base view
risk base busi weigh
spinraza competit potenti
rituxan biosimilar overhang
tecfidera ipr expect
management track record transform
late-stag limit
expect signific capit
management chang strategi
risk achiev price
faster expect launch new
rimegep competitor migrain data glutam platform valid drive
rimegep competitor migrain data glutam platform valid drive
deriv pt discount cash flow dcf analysi
assum wacc termin growth rate post
main revenu driver model rimegep
episod migrain lesser extent glutam platform
robust rimegep uptak episod migrain commerci
chronic migrain strong share addit neurolog indic
glutam platform net product sale driven sale
rimegep aggreg cgrp
platform ex-u sale aggreg sale trigriluzol bhv-
 ex-u
strong share rimegep episod migrain modest share
addit neurolog indic glutam platform
net product sale driven sale rimegep
ex-u commerci commerci
chronic migrain aggreg sale trigriluzol bhv-
 commerci ex-u
pipelin failur rimegep glutam platform molecul fail
develop process compani trade cash value-per-share
equal-weight biohaven lead
larg unmet need acut treatment
migrain phiii data suggest product
could differenti emerg
competitor particularli safeti howev
believ valuat reflect posit
aspect thu see balanc
signific pipelin driver troriluzol bhv-
gener encourag
data troriluzol achiev
statist signific result phii/iii
spinocerebellar ataxia sca program
result drug inabl differenti
placebo seem trial/ind specif
current see limit read
glutam program expect key
data glutam platform
rimegep file
commerci clariti
glutam data particularli troriluzol
risk achiev price
regulatori hurdl rimegep
poor safety/efficaci data
base busi brineura vosoritid bmn drive valu
base busi brineura vosoritid bmn drive valu
aldurazym pipelin vosoritid bmn greatest
extra strength pipelin assum expect growth base
busi drug pipelin vosoritid bmn becom even larger
driver valu
pipelin contribut assum base busi perform well come
year also pegvalias approv trifecta vosoritid bmn
 bmn launch model probabl success
vosoritid bmn bmn
pipelin current approv drug assum drug
pipelin unabl gener satisfactori result gain market approv
bear scenario
leader orphan opportun biomarin
uniqu player core
compet orphan drug set apart
larg cap emphas market
target larger popul
strength base busi establish
valu base busi vimizin naglazym
kuvan aldurzym contribut
revenu given natur market outsid
competit unlik allow base
busi creat valuat backstop
deep pipelin offer plenti
opportun upsid biomarin deep
wide product pipelin multipl drug
potenti launch end
vosoritid bmn possibl
blockbust contribut upsid
pipelin opportun near-term focu
investor focu pipelin
opportun nearer-term launch
pegvalias pku well potenti
blockbust vosoritid achondroplasia
bmn gene therapi treatment
find patient drive sale
base busi base busi drug
still grow recent launch
vimizim still leg drive sale
biomarin abil steadili find new patient
grow revenu opportun
bmn hemophilia gene therapi
bmn could signific impact
valuat matur data becom
risk achiev price
neg updat key pipelin drug
highlight safeti efficaci risk
bmn failur phase
focu orphan asset price could
impact investor view base busi
pipelin upsid particularli impact
termin valu busi
expens manag particular
meet year oper margin target
million per share basi indic
royalti licens revenu
equiti loss biomarin/genzym llc
share outstand ep
million per share basi indic
equival
properti plant equip net
account payabl accru liabil
total liabil sharehold equiti
million per share basi indic
adjust reconcil net loss net cash use oper activ
depreci amort expens
chang oper asset liabil
account payabl accru liabil
net provid use oper activ
purchas properti plant equip
purchas available-for-sal invest
sale matur invest
net provid use invest activ
proce exercis stock option equiti
proce issuanc common stock
proce issuanc retir debt
net provid use financ activ
effect exchang rate chang
chang cash cash equival
cash equival begin year
cash equival end year
market secur end year
car-t bcma sickl cell beta-thalassemia gene therapi drive risk/reward
car-t bcma sickl cell beta-thalassemia gene therapi drive risk/reward
signific sickl cell uptak bcma car-t high share relaps set
modest beta-thalassemia penetr assum larg portion
elig scd patient receiv gene therapi signific portion
new incid popul receiv therapi beta-thalassemia assum
row penetr assum strong launch penetr
front line patient
uptak beta-thalassemia us/eu strong bcma car-t uptak
line moder sickl cell penetr scd project peak ww sale
assum oral competit baselin factor organ damag
stroke etc may limit uptak gene therapi beta-thalassemia
assum penetr develop market scd price
lentiglobin fail make market assum scd
beta thal make market model cash-bas valu assum
launch
equal-weight
compani progress sickl cell diseas
reflect valuat see car-t
bcma program main upsid
believ initi data repres
proof-of-concept allow us valu
penetr sickl cell market
penetr beta-thalassemia
see initi bcma car-t data
strong highli valu segment
peak sale assum
maintain major share
competit compani
addit car-t data durabl
data earlier line therapi
addit data follow-up
lentiglobin beta-th scd studi
new clinic program either gene
therapi car-t gene edit
risk achiev price
potenti efficaci safeti concern
would inhibit manag team
bring market addit
indic earlier line
efficaci lentiglobin given
limit number patient potenti
variabl patient engraft diseas
sever patient respons
safeti lentiglobin given lack
long-term follow-up limit patient
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model avapritinib
deeper penetr avapritinib assum deeper penetr avapritinib
line therapi kit driven gist form sm well higher
expect
avapritinib launch assum avapritinib launch pdgfr
resist gist kit gist kit driven gist project
launch appli risk
assum avapritinib use pdgfr resist gist popul
avapritinib indic unapprov
avapritinib key valu driver
blueprint drug like approv
pdgfra exon mutant gist fourth-
line gist earli gist
potenti earli data system
repres
underappreci opportun
diseas rel treatment
option current avail drug
fairli ineffect poorli toler
blueprint present earli dose rang
data show promis efficaci
appear promis though
competit dynam ret-
inhibitor could well impact
show tki highli
primari driver blueprint
avapritinib kit pdgfr mutant gist
well sm
risk achiev price
clinic failur avapritinib
due lack efficaci emerg
earlier stage pipelin fail advanc
collabor yield viabl
equal-weight thesi base lack
signific clinic catalyst ahead
omecamtiv mecarbil phase data
cautiou reldesemtiv given data
sma al
efficaci galactic-hf
omecamtiv mecarbil phase data
risk achiev price
data faster-than-expect advanc
phase data galactic-hf
termin earli futil follow
pt deriv dcf use
sale adjust revenu use probabl
success po om reldesemtiv al
reldesemtiv sma
greater market share bull case assum greater adopt
omecamtiv mecarbil reldesemtiv
om commerci begin base case assumpt
describ price target methodolog
product candid fail advanc unabl advanc
product candid trade cash value-per-share
step viaskin peanut program drive risk/reward
step viaskin peanut program drive risk/reward
deriv pt dcf base forecast dbv peanut
rate termin growth rate
modest share viaskin peanut commerci viaskin milk
viaskin egg viaskin peanut launch late gener peak ww sale
viaskin milk viaskin egg launch
respect obtain minim share achiev global
sale
modest uptak viaskin peanut commerci viaskin milk
viaskin egg viaskin peanut launch late gener
global sale contribut viaskin milk viaskin egg
given current regulatori issu viaskin peanut assum
probabl success
regulatori failur viaskin peanut commerci viaskin milk
and/or viaskin egg share trade cash value-per-share
equal-weight
gener mix phiii top line profil
manag subsequ pull back
bla viaskin peanut follow issu
highlight fda bla recent
resubmit accept fda
review believ regulatori
progress viaskin peanut bla
particularli anticip advisori
committe meet repres next key
step dbvt
viaskin milk viaskin egg repres
potenti upsid driver target
market high unmet need howev
given earli natur program
mix late-stag result viaskin peanut
egg milk program factor
bull case modest uptak
anticip advisori committe meet
discuss viaskin peanut bla
regulatori action competitor peanut
allergi product candid anticip
risk achiev price
delay regulatori progress viaskin
lack support viaskin peanut
anticip fda advisori committe
greater expect competit
dbv nsdq dbvt
cost expens
sale
research develop
sell gener administr
non- adjust
research develop
gener administr
st invest
cash equival
inventori work progress
custom account receiv relat receiv
properti equip net
supplier account payabl relat payabl
premium relat share capit
total liabil stockhold equiti
adjust reconcil net loss net cash use oper activ
effect exchang rate chang cash cash equival
net decreas increas cash cash equival
cash equival begin period
cash equival end period
depreci amort
expens relat share-bas payment
chang oper asset liabil
inventori work progress
net cash use oper activ
acquisit properti plant equip
acquisit intang asset
acquisit non-curr financi asset
cash flow relat invest transact
net cash use invest activ
increas condit advanc
decreas condit advanc
capit increas net transact cost
cash flow relat financ activ
net cash provid financ activ
program al alzheim parkinson bbb platform drive risk/reward
program al alzheim parkinson bbb platform drive risk/reward
pt base dcf base case forecast
parkinson al alzheim bbb platform
discount rate assum termin growth cash
greater alzheim market share success idiopath parkinson
bull case assum market share al market share
alzheim share total parkinson popul alzheim
risk-adjust us peak sale program
program
risk-adjust success alzheim good probabl success
mutat valu bbb program base case assum
market share al market share alzheim share
mutat parkinson us peak risk-adjust sale
program program bbb program repres
total peak revenu
alzheim success mutat parkinson valu bbb
program approv al alzheim approv
parkinson al program gener peak revenu
program gener peak revenu bbb program repres
peak revenu
overweight thesi base
confid manag abil
inflect product histor
difficult treat area neurosci
believ manag right
process inflect success use
genet target biomark target
engag parallel invest
improv success initi target
repres initi yardstick
opportun greatli expand treatment
engag inhibitor
engag data patient
program
potenti evid activ idiopath
initi preclin clinic data
demonstr util bbb
risk achiev price
preclin clinic safeti signal
program
inabl advanc
program clinic test due poor
efficaci concern safeti signal
failur bbb program greater
success competitor similar program
demonstr safe administr human ip resolut success
demonstr safe administr human ip resolut success
pt deriv dcf use discount rate
edita abl develop commerci therapi receiv widespread
uptak therapi launch us eu treat
cure address popul command premium
price gener peak ww sale edita also abl
realiz sale addit therapi car-t applic
non-malign hematolog dmd cf
therapi prove success addit therapi obtain modest
success therapi launch us eu treat
cure address popul gener peak ww
sale edita abl develop success therapi car-
hematolog dmd cf achiev sale
pipelin program fail edita abl commerci therapi
result valuat cash share
equal-weight
crispr gene edit platform
derisk oper standpoint
gear toward numer diseas
target howev deliveri long-term
safeti administ clinic relev
dose human need proven
edita system modular approach
may allow differenti
first diseas target
inherit retin dystrophi lower initi
risk prove gene edit work
human eye immun privileg
provid small contain area
suffici quantiti vector
overal see signific long-term
potenti edita remain equal-weight
initi therapi derisk clinic
progress program
program clinic
hematolog diseas genet diseas
lung liver
risk achiev price
ip outcom limit edita freedom
develop risk associ earli
natur pipelin timelin long
competitor could influenc investor
percept stock
tazemetostat promis therapi
potenti broad applic although
see tazemetostat intrigu
approv asset potenti broad
applic size opportun
remain outstand question es small
indic like provid drug
first fda approv fl much larger
indic howev data point
later line diseas ultim look see
data demonstr efficaci earlier line
maintain ew rate
pt deriv dcf use discount rate
termin growth rate beyond valu tazemetostat
primari driver
tazemetostat treatment fl
tazemetostat approv ramp well assum tazemetostat launch es
fl dlbcl appli risk adjust
dlbcl
tazemetostat launch strength later line assum tazemetostat
launch es fl dlbcl appli risk
adjust fl dlbcl respect
risk achiev price
safeti issu emerg prevent
develop tazemetostat
might suffici efficaci
compet current treatment
collabor fail result meaning
program fail compani valu cash
probabl success monoclon microbi therapi drive risk/reward
probabl success monoclon microbi therapi drive risk/reward
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model evelo lead monoclon microbi product candid
atop dermat psoriasi
signific share atop dermat psoriasi evelo inflamm
focus monoclon microbi launch atop dermat
psoriasi atop dermat evelo product gain share peak
patient control topic treatment psoriasi evelo obtain
share peak patient biolog oral respect assum
probabl success po atop dermat po psoriasi
estim peak pos-adjust revenu
modest share atop dermat psoriasi evelo product candid gain
share peak atop dermat patient control
topic treatment gain share peak psoriasi
patient biolog oral respect estim peak pos-adjust
revenu
program fail valu compani cash
treat system condit via gut-
bodi network nascent field evelo
signific clinic literatur recent
year support premis gut-bodi
network preclin data gener
date evelo lead product candid
inflamm oncolog encourag
initi phi data report recent lead
product candid demonstr
encourag efficaci signal psoriasi
scalabl sever potenti target
therapeut inher safe
deriv gut
phi data dose origin
formul psoriasi
phi data new formul
psoriasi atop dermat
initi phii studi
mild-to-moder psoriasi earli
phi data new formul
atop dermat
phi/ii data mss tnbc
relaps tumor
risk achiev price
earli setback microbiom
focus compani may weigh investor
futur phi readout replic
efficaci signal observ initi phi
unforeseen safeti signal
upcom
sale
research develop
gener administr
net loss comprehens loss
oper expens
non- adjust
research develop
gener administr
net incom attribut common stockhold
cash equival
prepaid expens current asset
properti equip net
total liabil stockhold equiti
adjust reconcil net loss net cash use oper activ
chang fair valu warrant liabil
sale properti equip
chang oper asset liabil
prepaid expens current asset
accru expens current liabil
net cash use oper activ
acquir acquisit epiva
purchas properti equip invest
proce sale properti equip
net cash use invest activ
net proce issuanc convert prefer stock
proce issuanc long-term debt
repay long-term debt
proce exercis stock option common stock
chang stockhold payabl
net cash provid financ activ
restat chang restrict
net decreas increas cash cash equival
cash equival begin period
cash equival end period
pt deriv dcf use discount
rate model peak us market share translat
peak sale rcc assum peak us market share
translat peak sale
greater peak market share rcc bull case assum
peak us market share translat peak sale
addit assum peak us market share rcc share
translat peak sale rcc
expect gradual launch base case assumpt
describ price target methodolog
lower long-term market share rcc greater-than-expect
competit pressur beyond cabozantinib market share declin
patent expir rcc reach share rcc
equal-weight believ
posit expect cabozantinib
rcc larg price share
limit clinic catalyst ahead
data earli
believ sale growth
gradual
phase data rcc earli
risk achiev price
cabozantinib earlier stage trial
posit expect new later
stage asset program announc
addit data report support
advanc cabozantinib indic
beyond rcc
slowli expect combin
studi cabozantinib earlier stage
trial succeed
updat antibodi drive risk/reward
updat antibodi drive risk/reward
pt base dcf use discount rate project free
cash flow base termin valu
onward use termin growth rate project revenu
lead product candid md dlbcl risk-adjust
strong uptak md dlbcl see strong uptak use
broadli across r/r front line dlbcl set base case
gener peak risk-adjust sale also gain
greater share higher-risk share lower-risk md gener peak
risk-adjust sale
modest uptak md dlbcl dlbcl gener risk-
adjust revenu assign
po probabl success dlbcl gener risk-
adjust md revenu
fail tumor type fail develop stage across
indic result forti seven trade cash value-per-share
overweight forti seven
believ earli clinic data gener
antibodi highli encourag across
oncolog indic could first-in-
class therapi new categori checkpoint
data gener date indic
potenti strong singl agent activ
well activ could complementari
anti-canc agent
progress toward us pivot studi
increment phi respons durabl
data azacitidin md aml
phi data studi avelumab
ovarian cancer
phi data studi cetuximab
colorect cancer
risk achiev price
poor efficaci and/or safeti data lead
stronger expect data
losmapimod efficaci phase ii studi drive risk/reward
efficaci phase ii studi drive risk/reward
pt deriv discount cash flow analysi assum
discount rate termin growth valu assum peak
impli us market share fshd adjust use
probabl success po
losmapimod receiv acceler approv phiib data biomark
earli clinic data suffici acceler approv losmapimod
preclin program advanc earli clinic studi
losmapimod approv full phiii program losmapimod meet
primari endpoint phase ii thu demonstr potenti treat fshd
fda requir full clinic program long-term follow-up fshd
patient scenario fulcrum requir conduct phase studi
losmapimod fail losmapimod fail receiv regulatori approv
trade cash value-per-share
believ fulcrum proprietari
target discoveri platform yield
import small molecul target genet
believ losmapimod promis
compound demonstr target
engag fshd higher
typic phiib probabl success clinic
studi see upsid potenti
acceler approv data
believ manag continu
find genet target exploit
small molecul see potenti
target engag muscl expect
studi data demonstr efficaci fshd
patient expect
demonstr efficaci fshd patient
expect
risk achiev price
question valu losmapimod
caus investor regul disregard
avail safeti data gsk prolong
timelin lower probabl
delay timelin posit data
filgotinib ra ibd pipelin asset drive risk/reward
filgotinib ra ibd pipelin asset drive risk/reward
deriv pt discount cash flow analysi use
wacc cash flow forecast expir
filgotinib patent main driver filgotinib
filgotinib still major driver assum greater share ra ad
ipf pipelin asset gener signific sale assum po
adjust peak sale filgotinib ra uc
cd total filgotinib mileston payment
ad gener peak po adjust global sale
ipf gener peak po adjust global sale
oa gener peak po adjust global sale
filgotinib drive forecast strong contribut ad ipf
pipelin asset assum po adjust peak sale filgotinib
ra uc cd
total filgotinib mileston payment ad gener
peak po adjust global sale ipf gener peak
po adjust global sale oa gener peak po
adjust global sale
filgotinib pipelin asset fail manag continu invest
 assum cash-per-share valu
overweight galapago
believ filgotinib addit pipelin
asset differenti carv
market share competit
filgotinib differenti profil versu
oral competitor xeljanz
olumi believ best class
efficaci cleaner safeti profil
especi anemia across indic
model peak po adjust global sale
filgotinib
filgotinib potenti approv
key inflammatori indic beyond
rheumatoid arthriti includ crohn
spondyl psoriat arthriti
data pipelin asset ad
ipf oa
encourag enough us
incorpor probabl adjust estim
molecul valuat await
matur data
main driver advanc
filgotinib ra ibd along continu
progress ipf oa ad program
risk achiev price
take signific time phase ii safeti
profil may assur protect
unknown side-effect broader phase
approv risk regulatori approv
assur potenti failur
gain approv one geographi
commerci risk ra market
competit number market
agent along agent develop
filgotinib pipelin product may
durat hcv sale hiv patent expir car-t/pipelin drive risk-reward
durat hcv sale hiv patent expir car-t/pipelin drive risk-reward
less rapid eros hcv franchis strong pipelin realiz drive bull
case hiv product revenu reach hcv busi gener
sale sale yescarta filgotinib
gilead respect
rapid hcv eros lower pipelin success bull case hiv
product revenu reach hcv busi declin
sale sale yescarta filgotinib
gilead respect
stabl hiv revenu quick hcv busi eros minim pipelin
success hiv product revenu hcv busi gener
sale littl pipelin valu
equal-weight gilead believ
offer signific absolut
upsid near-term catalyst
term upsid rel gilead
signific return capit share
repurchas low forward price-to-earnings multipl
offer downsid protect
believ hcv peak us
continu declin modestli
howev believ cash flow gener
robust
hiv gilead done good job
switch nave patient new
stribild complera genvoya
truvada/atripla still hold market
right mean signific number
still need switch howev given time
solid taf switch data believ
least half market switch
car-t gilead acquisit kite provid
potenti renew long term revenu
main driver hiv franchis
hcv franchis car-t franchis
pipelin capit deploy repres
key driver
updat agreement galapago
entitl gilead commerci right
outsid europ jak inhibitor filgotinib
may provid near-term upsid
approv varieti inflammatori
risk achiev price
unexpect competit hiv
rapid hcv eros
appreci consensu
failur car-t achiev signific
market penetr failur meaning
signific delay regulatori
progress jak inhibitor filgotinib
darzalex ofatumumab label expans studi coupl matur mid-lat
darzalex ofatumumab label expans studi coupl matur mid-lat
pt deriv dcf use discount
rate termin growth rate revenu driver model
darzalex late-stag partner product ofatumumab
teprotumumab well earli stage proprietari compound
upsid darzalex uptak ofatumumab success phiii greater risk-adjust
valu proprietari pipelin assum peak sale darzalex
ofatumumab peak sale pipelin peak sale
continu robust darzalex uptak ofatumumab success ms risk-
adjust valu proprietari pipelin assum peak sale
darzalex ofatumumab peak sale pipelin peak sale
assum blend probabl success
darzalex royalti valu bear case assum darzalex royalti
burden invest pipelin matur assum
greater competit out-year biosimilar cell therapi mm
base case
overweight thesi base
signific upsid skew risk/reward
proprietari pipelin given believ
darzalex royalti plu late-stag
partner pipelin alon account
current valuat genmab
believ darzalex royalti worth
coupl
late-stag pipelin ofatumumab ms
teprotumumab believ
ofatumumab teprotumumab could
believ earli mid-stag
proprietari pipelin under-valued
consensu repres compel
risk/reward valu proprietari pipelin
base case
bull case valuat
ofatumumab label expans ms
asclepio ii
teprotumumab approv
variou proprietari partner product
initi clinic readout
pivot phii data innovatv
tisotumab vedotin cervic cancer earli
risk achiev price
meet consensu expect
ofatumumab could fail late-stag trial
early-stag proprietari asset could fail
clinic success market penetr voxelotor previous drive
clinic success market penetr voxelotor previous drive
peak penetr voxelotor assum voxelotor demonstr
abil modifi lt marker scd pain sickl crise thrombot event
new standard care assum limit competit gene therapi
peak penetr voxelotor assum clinic success voxelotor
compar success gene therapi voxelotor gene therapi split
voxelotor fail case assum residu cash valu
market signific unmet medic
need voxelotor oral dose potenti
diseas modifi therapi posit well
compet market new therapi
decad market share suggest
us peak sale potenti
earli voxelotor data compel initi
data demonstr reduct sickl
cell improv red blood cell
marker hemoglobin reticulocyt ldh
believ data could translat
clinic outcom includ reduct
sickl crise pain thrombot event
market assumpt leav room
competit current model
peak penetr hbss leav room
gene therapi believ oral dose
could prefer gene therapi could offer
cur therapi could
prefer patient
regulatori progress potenti
commerci launch voxelotor
risk achiev price
regulatori setback failur voxelotor
greater success competitor therapi
gene therapi
epidiolex ramp drive gw share
epidiolex ramp drive gw share
pt deriv dcf use discount rate
termin growth rate beyond valu
program cannabinoid base therapi rare neurolog
epidiolex exce expect drug ramp well label indic
dravet lenox-gastaut strong label use expect revenu
use gradual ramp expect revenu exceed
epidiolex ramp slower expect assum drug ramp well
label indic less steepli anticip off-label use minim
gw market leader medic
applic cannabis-rel intervent
sativex approv eu epidiolex
approv fda
transfer schedul
june food drug
cannabidiol cbd oral solut
treatment seizur two rare sever
form epilepsi lennox-gastaut syndrom
dravet syndrom believ epidiolex
would wide use treatment
refractori pediatr epilepsi on-label
off-label
sale ramp epidiolex primari
driver share valu
risk achiev price
payer impos signific restrict
physician hesit prescrib
gwph adr british base
pt base dcf use discount rate project free
cash flow base termin valu
onward use termin growth rate project revenu
lead product candid tnbc muc
bull case assum achiev greater adopt ww peak risk
adjust sale assum commerci treatment line
mtnbc acceler adopt muc er cancer
base case assum launch mtnbc addit
revenu stream earlier line muc er larg enter
assign risk adjust use mtnbc ww risk adjust sale
bear case assum fail receiv approv indic
stock trade cash valu
equal-weight driven concern
around uncertainti approv timelin
requir follow
sidelin fda
continu believ efficaci
safeti data see signific
unmet need mtnbc believ approv
could see rapid adopt peak
believ obtain multipl
label expans increas asset total
address market studi front line
mtnbc muc er breast cancer could
remedi approv
phiii data random ascent
studi mtnbc treatment earlier line
data pivot phii studi trophi
muc hormon breast cancer
risk achiev price
management fail correct cmc-relat issu
competit landscap target
therapeut mtnbc muc increas
failur achiev signific label
expans earlier line therapi
jakafi perform oncolog dermatolog pipelin readout drive
jakafi perform oncolog dermatolog pipelin readout drive
deriv price target discount cash flow analysi
factor explicit revenu project use
discount rate termin growth rate
jakafi sale upper rang long-term guidanc clear blockbust
perform key late-stag pipelin asset strong contribut
early-stag pipelin jakafi sale peak total revenu
itacitinib first-lin gvhd gener peak sale
ruxolitinib cream gener peak sale across vitiligo atop
dermat early-stag pipelin contribut aggreg peak sale
jakafi sale midpoint long-term guidanc coupl strong
pipelin realiz jakafi sale manag long-term
guidanc peak total revenu approv
strong uptak late-stag pipelin asset itacitinib first-lin gvhd peak
sale ruxolitinib cream vitiligo atop dermat
aggreg peak sale aggreg peak sale
early-stag pipelin
jakafi sale manag guidanc modest royalti revenu
minim pipelin success jakafi sale peak royalti revenu
jakafi ex-u olumi peak iclusig sale
aggreg peak pipelin revenu
jakafi base busi room
grow hold right jakafi
ruxolitinib ex-u right held
novarti jakafi sale
grown y/i
y/i forecast
continu growth jakafi
meaning contribut label
expans graft versu host diseas
gvhd forecast peak jakafi sale
roughli midpoint
manag long-term guidanc
prior jakafi patent expir
pipelin effort come focu
late throughout
develop broad multi-asset pipelin
believ key area investor focu
phiii asset itacitinib gvhd
ruxolitinib cream vitiligo atop
effort fgfr inhibitor pemigatinib
first phiii readout itacitinib first-lin
gvhd expect first set
phiii ruxolitinib cream data expect
adjust sale itactinib
gvhd ruxolitinib cream
jakafi life cycl extens effort
pemigatinib bladder cancer also
expect
factor grow jakafi sale base
strong contribut late-stag
pipelin result find current
risk/reward valuat balanc
phiii data jakafi itacitinib gvhd
phiii data ruxolitinib cream atop
data pemigatinib bladder cancer
tumor agnost program
addit detail jakafi life cycl
phiii data jakafi steroid-refractori
chronic gvhd studi
phiii data itacitinib steroid-na acut
gvhd studi
nda submiss pemigatinib cca
expect
phiii data ruxolitinib cream atop
dermat
phii data inhibitor parsaclisib
phii data antibodi
updat jakafi life cycl extens
program
risk achiev price
 jakafi sale perform
poor phiii result itacitinib and/or
ruxolitinib cream either due outright safeti
and/or efficaci failur due result
clinic meaning
failur and/or minim success early-
stage pipelin asset
mileston contract revenu
cost expens
product revenu incl definite-liv intang amort
chang fair valu acquisition-rel conting consider
total cost expens
incom loss oper
unreal loss long-term invest
expens relat senior note convers
incom loss provis incom tax
provis incom tax
share use comput net incom loss per share
cash equival
prepaid expens current asset
restrict cash invest
properti equip net
accru current liabil
accumul comprehens incom
total liabil stockhold equiti
flow oper activ
in-process research develop
expens relat senior note convers
unreal loss long-term invest
chang fair valu acquisition-rel conting consider
chang oper asset liabil
prepaid expens asset
accru liabil
net cash provid use oper activ
flow invest activ
acquisit busi net cash acquir
purchas long-term invest
purchas market secur
sale matur market secur
net cash use invest activ
flow financ activ
proce issuanc common stock stock plan
proce issuanc common stock net
paid connect senior note convers
payment conting consider
net cash provid financ activ
effect exchang rate cash cash equival restrict cash invest
net increas cash cash equival restrict cash invest
cash equival restrict cash invest begin period
cash equival restrict cash invest end period
penetr durat ali therapi key valuat driver
penetr durat ali therapi key valuat driver
pt deriv dcf use discount rate
termin growth rate revenu driver model ali
market penetr us japan refractori frontlin
mainten treatment ntm
ali launch us japan achiev
penetr respect refractori ntm popul major
patient take form mainten treatment also forecast low
doubl digit penetr frontlin popul us japan peak sale
respect
ali launch us earli japan reach
penetr respect refractori ntm popul less
modest frontlin penetr us japan peak sale
ali achiev weak penetr patient refractori diseas
overweight insm given robust
data ali refractori induc ntm
patient derisk approv also provid
modest assumpt chronic dose
opportun note current data argu
investig label
geograph expans japan provid
addit lever see substanti
foreign sale larger ntm popul
prioriti review fda advisori
prepar japan file pmda
follow-up data long-term extens
convert studi full data
risk achiev price
failur reach market restrict
label target small portion
poor long term durabl driven
dropout safeti signal less differenti
standard treatment
delay life cycl manag studi
need obtain robust mainten
breo anoro success drive risk reward
breo anoro success drive risk reward
pt deriv dcf assum discount rate
breo anoro captur signific share market bull case
assum breo anoro characterist qd dose breo lack
ic anoro drive major share copd asthma
prescript given sluggish launch drug comfort
physician approv laba/icss see scenario unlik
model peak ww sale breo anoro
trelegi
breo anoro sluggish launch case assum breo
anoro gain modest share copd/asthma prescript model peak ww
sale breo anoro trelegi
dcf valu equiti stream royalti less net-debt
breo anoro falter commerci bear case assum breo anoro
fail gain commerci traction model ww sale breo anoro
trelegi
underweight see limit
upsid valuat impli
potenti gsk consolid royalti
interest breo/anoro
launch breo anoro
sluggish far
breo qd dose potenti complianc
advantag howev top-line result
breo phiii trial suggest profil similar
patient switch approv laba/icss
compet least initi
laba/ class mean growth anoro
expect maba/tripl combo
cannib sale breo anoro
patient need come laba/
lama/laba take one drug
key driver model includ
royalti breo launch anoro
launch trelegi approv
risk achiev price
breo and/or anoro may sell better
compani may potenti
busi develop transact may
spinraza grow focu shift tegsedi
spinraza grow focu shift tegsedi
pt deriv dcf use discount rate
termin growth rate beyond valu ioni advanc
driven revenu upsid across lead pipelin drug assum rapid
penetr spinraza thrombocytopenia concern physician
patient allow tegsedi success hit market appli modest pipelin
valu drug includ ionis-fxi
ionis-htt
spinraza tegsedi drive valu assum rapid spinraza penetr upon
launch tegsedi sale grow thrombocytopenia limit launch appli modest
pipelin valu drug includ ionis-fxi
apo -l ionis-htt
ioni unabl launch addit product base case scenario assum
spinraza sale fall short expect commerci challeng
emerg respect platform pipelin drug
long haul view antisens
promis drug develop
platform equal-weight ioni
believ safeti toler concern
like remain overhang share
tegsedi launch underway expect
thrombocytopenia concern weekli
blood monitor could put damper
spinraza blockbust treatment
type sma tegsedi like increas
focu drug launch
thrombocytopenia particular -- could
challeng tegsedi
spinraza continu grow spinal
muscular atrophi sma increas
emphasi type patient investor remain
wari compet gene therapi novarti
share would driven compani
extens develop pipelin
numer near- medium- long-term
risk achiev price
news flow regard either success
failur ioni pipelin could lead
swing share valu
data ioni pipelin alter
efficaci and/or safeti profil
clinic data competit program
alter dynam market ioni
current pursu
use wacc termin growth rate
linzess becom domin player ib cic market linzess
prefer treatment ib cic domin prescript
product take greater share over-the-counter therapi push past
linzess remain steadi grower linzess gradual grow share ib cic
market beat brand player make headway
expens over-the-counter therapi net sale push past
linzess slow ibs-c cic market slow tough competit take share
equal-weight ironwood
expect linzess growth like stabil
multipl quarter
ration post expect spin
cyclerion push ironwood
deeper profit
key revenu driver model
risk achiev price
enabl upside/downsid versu
one compani pipelin drug could
achiev superior data lead us
increas expect regard
ration exceeds/fal short
expect lead upside/downsid
data ucd program drive risk/reward
data ucd program drive risk/reward
pt deriv dcf use discount
rate termin growth rate revenu driver model
ucd
greater diagnosi rate larger set address patient ucd
vs base case ucd program gener peak risk-
adjust global sale respect assum
kaleido program approv overt minim patient appli
risk adjust ucd program respect
ucd program approv therapeut receiv signific
patient uptak ucd program gener peak risk-adjust
global sale respect uptak drive
bulk revenu due greater share higher price compar eu
assum kaleido program approv overt
popul appli risk adjust ucd
kaleido pipelin fail ucd program fail kaleido unabl
commerci mmt therapi assum share trade cash
value-per-share case
overweight kaleido thesi
base success commerci
mmt product treatment urea
cycl disord ucd hepat
kaleido take differenti approach
toward leverag gut microbiom
develop synthet analyt
capabl enabl kaleido gener
product candid rapidli kaleido
test mmt candid human non-ind
studi mmt complex carbohydr
molecul relat gra
gener recogn compound
allow kaleido progress directli
phii studi ind set-up
may facilit speed market
abil progress product candid
strong proof-of-concept human
non-ind studi healthi
toler profil abil reduc
achiev statist signific base
earli yet encourag result
believ could lead posit result
clinic studi patient could progress
becom viabl therapeut ucd
ucd kaleido second lead
program addit program
also plan infect caus multi-
kidney diseas cardiovascular diseas
program current earli
believ could becom futur pipelin
driver data lead ucd
program prove posit
data non-ind studi
data phii studi ucd
ind
data patient colon
mdr pathogen
risk achiev price
poor efficaci data surpris neg
safeti signal non-ind studi
poor phii data ucd patient
make investor question viabil
platform
neg data microbiom
compani weigh share
regulatori chang compromis
kaleido abil conduct non-ind studi
human could lengthen time
market push product revenu
futur
sale
research develop
gener administr
net loss comprehens loss
oper expens
non- adjust
research develop
gener administr
net incom attribut common stockhold
cash equival
prepaid expens current asset
due relat parti
properti equip net
accru expens current liabil
total liabil stockhold equiti
adjust reconcil net loss net cash use oper activ
chang fair valu deriv warrant liabil
chang oper asset liabil
prepaid expens current asset
due relat parti
accru expens liabil
net cash use oper activ
purchas properti equip
net cash use invest activ
payment defer issuanc cost
proce issuanc debt net issuanc cost
payment issuanc cost relat debt
proce prefer stock financ net issuanc cost
proce issuanc stock
proce exercis stock option
payment relat capit leas
net cash provid financ activ
net decreas increas cash cash equival
cash equival begin period
cash equival end period
durabl data wet age-rel macular degener drive risk/reward
durabl data wet age-rel macular degener
pt deriv dcf use discount
rate revenu driver model kodiak lead anti-vegf
candid retin diseas
commerci multipl retin diseas strong uptak
commerci wet diabet eye diseas peak
penetr probabl success po total risk-adjust
revenu grow
commerci limit set retin diseas modest
uptak commerci wet peak
penetr probabl success po total risk-adjust revenu
grow peak
fail kodiak unabl develop trade cash
overweight thesi base
success commerci
sever compani commerci
anti-vegf therapi treatment
retin diseas burden monthli
bimonthli treatment reduc long
design extend therapeut
durabl compar current therapi
preclin data well-establish rabbit
model demonstr extend durabl
clean safeti profil
initi clinic data direct phib
phii interim analysi demonstr
demonstr efficaci durabl
wet diabet eye diseas
multipl studi begin
risk achiev price
investor question valu
increas toxic advanc patient
posit data competitor could weigh
market share especi
competitor data arriv prior pivot trial
margituximab posit updat proprietari dart bispecif platform
posit updat proprietari dart bispecif platform
advanc therapeut program
strong uptak margituximab enoblituzumab bull scenario assum
sale treatment breast gastric cancer scenario also
assum enoblituzumab achiev success trial launch
treatment multipl solid tumor includ pipelin valu potenti
margetuximab peak margetuximab achiev modest success
studi find place nich therapi refractori breast cancer patient
includ pipelin valu potenti dart platform
failur commerci proprietari partner program macrogen
gener product relat revenu
equal-weight macrogen
macrogen one pure play
biotech broad bispecif antibodi
platform though believ platform
substanti potenti would like
see ampl data appli higher
like efficaci treatment cancer
manufactur packag dart
broadli applic implement
beyond oncolog effort underway
treat autoimmun infecti
diseas dart could effect safeti
toler issu could present
program offer support
valuat though modest
expect margetuxemab direct
valid target could yield
sale provid downsid support
respect target enoblituzumab
think could offer greatest util
combin checkpoint inhibitor
would like see data
increas expect
clinic data dart bispecif
antibodi beyond
updat phase compound
margetuximab bolster downsid
support valuat
clinic updat includ
risk achiev price
pipelin failur partner proprietari
neg safeti efficaci data
therapeut program
poor data bispecif program
cast doubt bispecif overal
deriv pt dcf base forecast
mrna base product candid use
discount rate termin growth rate
strong share pipelin program bull case valu
program base case well oncolog relaxin heart
failur fabri program risk adjust vari product
launch begin gener sale
flow flow
success pipelin program base case valu rsv
cmv hmpv pcv kra cancer vaccin program vegf-a
rare diseas program mma pa pku risk adjust vari
product launch begin gener sale
flow
flow
product candid face technology/clinical/regulatori failur
therefor gener revenu share trade cash value-per-share
overweight moderna compani
taken industri approach
develop mrna base therapeut
rapidli gener broad pipelin
program candid enter
mrna drug develop platform
diversifi scalabl compar
competitor mrna space
valid broad partnership
merck astrazeneca
signal gener preclin
earli clinic studi date indic
mrna therapeut activ
across wide varieti modal
indic rang prophylact
cancer vaccin rare diseas believ
mani program repres
abl screen product
candid rapidli due digit
manufactur capabl compani
plan progress five new product
candid clinic everi year
coupl initi proof-of-concept data
area enzym replac
disord would valid key area
approach allow signific
increas pipelin probabl success
addit earli clinic stage data
intratumor i/o local regen
therapeut modal
expect
nomin addit drug candid
risk achiev price
initi data platform
beli investor expect caus
investor write-off subsequ readout
delay abil gener
stronger expect competitor data
mavacamten drive risk/reward
mavacamten drive risk/reward
pt deriv discount cash flow analysi assum
discount rate termin growth rate assum peak us
market share ohcm nhcm dcm
translat peak us sale
respect adjust use probabl success po
ohcm po nhcm po dcm
higher po pipelin product assum higher po dcm
ohcm nhcm follow posit data readout
sale estim base conserv market share risk-adjust
base case assumpt describ price target methodolog
precis medicin platform fail unabl advanc product
candid trade cash value-per-share
overweight myokardia
well-defin subgroup unmet medic
need potenti grow beyond
promis phase data
gener lead asset mavacamten
show reduct left ventricular outflow
tract lvot gradient week
provid opportun upsid
enter clinic advanc
nhcm
phase data dcm
ohcm
risk achiev price
poor efficaci concern safeti data
maverick-hcm lower
probabl success nhcm
concern safeti data
phase prevent advanc
studi
pt deriv dcf use discount rate
termin growth rate beyond valu nabriva antibiot
lefamulin achiev strong ramp inpati outpati set lefamulin
achiev peak sale contepo reach sale
expect gener might enter market
lefamulin achiev modest share iv use lead oral use discharg set
risk adjust lefamulin sale expect reach
contepo approach risk adjust sale
stock valu cash
lefamulin novel mechan action
provid need option cabp nabriva
lefamulin first-in-class system
pleuromutilin develop oral iv
use treat community-acquir bacteri
pneumonia cabp lefamulin cabp
target spectrum activ novel
mechan action resist seen
date provid import altern
option treatment cabp
expect gradual commerci adopt
lefamulin sale driven use
inpati set nabriva initi
account said repres
opportun drug
launch rep meant cover
target account gain
formulari access key highli
acquisit zavant add second first-
in-class antibiot portfolio contepo
first-in-class epoxid could
potenti approv cuti although
opportun somewhat modest
key valu driver commerci
ramp lefamulin
risk achiev price
contepo regulatori process could
lefamulin and/or contepo sale fail
potenti addit dilut financ
pt base dcf base case forecast
metastat melanoma nsclc bladder cancer use
discount rate termin growth cash flow
higher probabl success greater market share assum
probabl success melanoma nsclc bladder cancer also
assum higher market share result peak sale across indic
risk-adjust success assum probabl success
across melanoma nsclc bladder cancer assum
commerci melanoma launch nsclc bladder
cancer assum peak sale across indic
fail clinic develop fail across indic
share trade cash value-per-share
overweight neon therapeut
believ neoantigen relev vaccin
target believ improv
efficaci tradit immun target
agent
initi data support immun
respons median data top
line result suggest lead
product candid increas
durabl top therapi await
full data order
draw detail conclus
manag industri
platform informat need produc
person vaccin
present detail data
medic meet
insight phii melanoma
studi design expect
data studi evalu
keytruda chemotherapi
nsclc expect
risk achiev price
failur initi clinic
neoantigen approach
mrna gener superior data peptid
neoantigen screen technolog still
novel neon platform may sub-optimal
compar other may select
wrong neoantigen could lead poor
revenu
research develop
gener administr
income/ loss oper
accret redeem convert prefer stock redempt valu
net incom loss attribut common stock
non- adjust
research develop
gener administr
net incom attribut common stockhold
cash equival
prepaid expens current asset
properti equip net
total liabil stockhold equiti
adjust reconcil net loss net cash use oper activ
depreci amort
net amort premium discount market secur
gains-to-loss sale properti equip
chang oper asset liabil
prepaid expens current asset
accru expens current liabil
net cash use oper activ
purchas market secur
sale matur market secur
purchas properti equip
proce sale properti equip
net cash use invest activ
proce issuanc seri
proce issuanc seri
proce exercis stock option
repurchas unvest restrict common stock
payment initi public offer cost
proce common stock offer
net cash provid financ activ
net decreas increas cash cash
cash equival begin period
cash equival end period
pt deriv dcf use discount
rate assum peak us market share td also model
peak us market share opicapon parkinson translat
ingrezza sale growth beat expect assum peak market share
vy-aadc abl reach market late
unadjust us ingrezza sale td base case assumpt
detail price target methodolog
slower growth td sale bear case assum lower peak us market
share ingrezza td translat peak sale
addit assum vy-aadc unsuccess reach market
overweight thesi driven ingrezza
even though question
whether growth slow think
possibl achiev peak sale
partnership voyag offer
exposur larg market earlier
end-of-phas meet
potenti approv orilissa uterin
risk achiev price
ingrezza sale growth td may continu
deceler
vy-aadc pivot studi enrol
expect safeti concern aris
pt deriv discount cash flow analysi assum
discount rate termin growth valu assum peak
impli us market share
adjust use probabl success po
higher po assum higher po peak share follow posit
sale estim base conserv market share risk-adjust
base case assumpt describ price target methodolog
immunotherapi platform fail unabl advanc product
candid trade cash value-per-share
overweight nextcur
defin subgroup unmet medic need
potenti expand beyond
sinc express
overlap tumor tumor
respond therapi
initi cut data phase show
promis earli sign activ
addit program pipelin
candid find-io platform
provid opportun upsid enter
clinic advanc develop
phase proof-of-mechan data
solid tumor nov societi
immunotherapi cancer
ind solid tumor
phase proof-of-concept data
phase proof-of-mechan data
phase proof-of-concept data
risk achiev price
poor efficaci and/or safeti data lead
product candid lower po
lack advanc early-stag pipelin
equal-weight base key
unknown risk associ launch
andexxa await addit formulari
updat clariti launch metric
need physician support
factor xa antidot consider bleed
signific potenti devast
complic anticoagul
revenu driver model
launch perform andexxa
us eu row
risk achiev price
andexxa launch could poor
drug may obtain signific uptak
andexxa could face execut
andexxa becom standard care bleed model detail follow
andexxa launch us eu andexxa peak
ww sale
andexxa major driver valuat model detail follow
andexxa launch us eu andexxa peak ww
sale
andexxa achiev base case peak sale assum andexxa
slow ramp modest us penetr andexxa ww sale peak
million except per-shar data
collabor licens revenu
interest incom net
net incom portola non-gaap
million
equival
account interest receiv
prepaid expens current asset
properti equip net
accru liabil
current portion long-term debt
total liabil sharehold equiti
million
amort premium invest secur
chang reserv uncertain tax posit
issuanc convert prefer stock licens
loss dispos leasehold improv
reevalu prefer stock warrant liabil
chang asset liabil
account interest receiv
pre-paid current long-term asset
accru compens employe benefit
accru liabil
net cash provid use oper activ
purchas properti plant equip
increas restrict
purchas intang asset
purchas short-term invest
proce sale short-term invest
proce matur short-term invest
net cash use invest activ
repay debt
proce issuanc common stock
dividend non-controlling interest srx cardio
proce long-term note payabl net
proce long-term oblig collabor
repurchas unvest common stock
proce issuanc convert prefer stock
proce exercis warrant
net cash provid financ activ
chang due restat
chang equival
equival begin year
equival end year
market secur end year
pt deriv discount cash flow analysi assum
discount rate termin growth valu assum peak us
market share neuronopath gaucher diseas ngd
parkinson diseas mutat pd-gba adjust
use probabl success po respect
higher po pd-gba assum higher po peak share posit
base case assumpt describ price target methodolog
gene therapi platform fail prevail unabl advanc product
candid trade cash value-per-share
overweight prevail compani
patient subpopul unmet medic
preclin data suggest
efficaci safe anim
glucocerebrosidas gcase increas
glycolipid accumul reduc motor
function improv -synuclein
accumul reduc
de-risk vector track
record safeti efficaci support
recent approv novartis/avexi
zolgensma infant sma type
provid opportun
upsid enter clinic
advanc develop
upcom catalyst
ind file frontotempor
begin phase type gaucher
begin phase type gaucher
initi phase data type
biomark data
clinic readout
risk achiev price
poor efficaci and/or safeti data lead
product candid lower
lack advanc early-stag pipelin
program osteoporosi drive risk/reward
program osteoporosi drive risk/reward
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model tymlo osteoporosi risk adjust sale
elacestr neg metastat breast cancer
market leadership growth osteoporosi limit pressur
forteo gener risk-adjust elacestr bull case assum
tymlo pen patch achiev acceler switch forteo user
minim impact gener ww peak sale
pen patch elacestr respect
competit uptak tymlo commerci long term market
transfer patch probabl success po elacestr
base case assum tymlo obtain competit formulari posit
also commerci patch assum
modest pressur forteo gener assum gener price line
tymlo ww sale tymlo pen patch elacestr
respect
loss treatment popul forteo gener poor commerci
patch elacestr fail bear case assum tymlo pen increasingli
pressur entri multipl forteo gener patch fail
substanti grow anabol market ww peak sale
pen patch respect
overweight radiu compani
osteoporosi platform gener solid
data commerci pen earli sign
encourag launch lead us believ
tymlo captur sizeabl portion
market transfer tymlo pen
tymlo patch establish sticki
patient popul face forteo
addit program breast cancer
contribut signific upsid valuat
believ demonstr
encourag data current standard
continu focu quarterli tymlo
time launch price potenti
updat phiii studi underway
patch
risk achiev price
disappoint launch trajectori tymlo
track prescript data formulari
failur defend market share
gener includ inabl bring patch
market
elacestr fail demonstr
improv standard care
eylea dupix drive risk-reward
eylea dupix drive risk-reward
better dupix penetr atop dermat asthma assum
us eylea row eylea sarilumab us
sale us dupilumab sale also
assum injunct place sale praluent
sarilumab me-too compar actemra strong dupix penetr
asthma atop dermat assum us eylea
row eylea us sarilumab sale
us dupilumab sale assum probabl
injunct sale praluent
praluent remain market sarilumab still me-too
modest dupix launch eylea face greater branded/biosimilar
competit assum us eylea row eylea
contribut praluent given complet injunct
modest row praluent sale sarilumab us
sale dupilumab sale
equal-weight regeneron
investor heavili scrutin dupix
prescript data sinc launch atop
dermat ad april believ
consensu still factor substanti sale
dupix ad well asthma see
risk/reward skew slightli
posit given steadi launch ad
recent approv asthma emerg
pipelin i/o see littl room near-
dupix initi launch trajectori
dupix encourag ad see
dupix durabl asset asthma
current project dupix sale
across atop dermat
praluent factor watch
develop new trial proceed
sanofi/regeneron
 praluent inflect come quarter
kevzara sarilumab see kevzara
me-too forecast sale
main driver dupix dupilumab
eylea emerg i/o pipelin
risk achiev price
unexpect flatten dupix
dupilumab launch trajectori
disappoint uptak asthma
competit success wamd space
limit uptak i/o asset
success use
success use partner proprietari program drive
technolog partner proprietari program drive
pt deriv dcf use discount rate
termin growth rate valu proprietari partner
commerci proprietari partner program model
strong uptak indic proprietari program
hofh mp wet respect gener peak
sale partner program mp iiia sma partnership
ultragenyx dimens dmd gene therapi sale gener peak
royalti revenu
commerci proprietari partner program model
modest uptak indic proprietari program
hofh mp wet respect gener peak
sale partner program mp iiia sma partnership
ultragenyx dimens dmd gene therapi revenu gener peak
royalti revenu
failur commerci proprietari partner program
receiv royalti avexi gener product relat
revenu bear case consist cash value-per-share well valu
royalti novartis/avexi sma program eu
overweight regenxbio believ
compani technolog platform
alreadi broadli licens across
potenti transform method
safe effect deliv gene
known target clear endpoint
reduct hofh reduct gag
accumul mp mp ii
arrang de-risk platform
help reduc binari risk face
success licens program use
vector deliveri method
reduc technic risk face proprietari
recent posit gene therapi data
help de-risk broader gene therapi
data/upd wet
hofh program
advanc
program mp mp ii respect
updat avexi sma program
technolog license
risk achiev price
pipelin failur partner proprietari
neg safeti efficaci data gene
therapi program develop
either technolog license gene
therapi compani use vector outsid
platform
cost expens
sale
research develop includ amount relat parti
gener administr includ amount relat parti
accret dividend convert prefer stock prefer unit
net gain extinguish prefer stock
non- adjust
research develop
gener administr
st invest
cash equival
properti equip net
due relat parti servic agreement
convert prefer stock prefer unit
accumul comprehens loss
total liabil stockhold equiti
adjust reconcil net loss net cash use oper activ
non-cash consider receiv licens grant
imput interest relat parti promissori note
net amort premium accret discount market debt secur
depreci amort
chang oper asset liabil
due relat parti servic agreement
net cash use oper activ
purchas sale market secur
purchas properti plant equip
net cash use invest activ
proce issuanc common stock
proce relat parti promissori note
net cash proce issuanc prefer stock
proce exercis stock option
proceed issuanc seri convert prefer stock
proce issuanc seri convert prefer stock
net cash provid financ activ
effect exchang rate chang cash cash equival
net decreas increas cash cash equival
cash equival begin period
cash equival end period
pt deriv dcf use discount rate
termin growth rate beyond valu rhythm program
orphan genet disord obes
setmelanotid approv launch pomc null lepr defici
setmelanotid data bardet-biedl syndrom bb alstrm
suggest drug could exceed expect indic rais
confid combin phiii trial
setmelanotid like reach market pomc null lepr
defici data bardet-biedl syndrom largest valu driver
model appear promis await data move risk
adjust higher incorpor alstrm risk
adjust estim peak sale setmelanotid
setmelanotid fail reach market rhythm trade cash
compel efficaci setmelanotid
two ultra-orphan diseas may result
setmelanotid underway data
expect studi
success would enabl regulatori
bardet-biedl signific
opportun rhythm pursu bardet-biedl
syndrom alstrm syndrom
addit indic rhythm present
data indic suggest
setmelanotid could offer benefit
patient phiii trial examin
indic set begin later year
increas rate diagnosi upon launch
key challeng import lever
setmelanotid commerci success
view increas test diagnosi
rate genet disord obes
patient target ideal candid
setmelanotid therapi current
undiagnos anticip
avail therapeut target
increas test diagnosi rate
believ rhythm would need invest
meaning captur patient
realiz potenti market opportun
key valuat driver perceiv clinic
regulatori risk setmelanotid
syndrom pomc heterozyg obes
risk achiev price
fail clinic trial setmelanotid
rhythm unabl enrol pivot trial
orphan indic
potenti dilut financ
initi rct data diseas ind file drive risk/reward
initi rct data diseas ind file drive risk/reward
pt deriv dcf use discount
rate termin valu onward base
termin growth rate valuat assign credit rubiu rare
diseas oncolog platform
commerci rare diseas oncolog immunolog strong
uptak commerci rare diseas pku gout
homocystinuria oncolog nsclc immunolog pemphigu vulgari
probabl success po pku gout
homocystinuria nsclc pemphigu vulgari total risk-
adjust revenu grow primari
revenu contributor peak pku gout
commerci rare diseas oncolog modest uptak
commerci rare diseas pku gout homocystinuria
nsclc within oncolog pku assign po gout homocystinuria
valu po nsclc assign po pku
commerci product candid launch
total risk-adjust revenu grow
primari revenu contributor peak pku gout
red platform fail rubiu unabl develop rct product candid
trade cash value-per-share
overweight thesi base
broad safe potenti applic
rubiu red platform could gener
diseas oncolog immunolog
pose white blood cell therapi like car-
includ broader applic off-the-
shelf approach improv safeti
rapid scalabl manufactur
preclin data encourag
date particularli rare diseas
platform ind applic lead
product candid
phenylketonuria pku approv fda
key risk across rubiu rare
diseas program deliveri risk
believ posit initi data
patient would address investor concern
significantli derisk rare diseas
program includ refractori gout
initi phi/ii studi
interim data patient
subsequ ind file futur rct
product candid
poor safeti and/or efficaci data rtx-
would like caus investor question
rubiu abil gener effect
investor may subsequ question
valu red platform assign limit
valu rare diseas oncolog
short circul time would
impair commerci prospect
platform could lead limit efficaci
posit data competitor either
platform compani
weigh rubiu share especi
competitor data arriv prior meaning
dataset rubiu
accret seri redeem convert prefer stock redempt valu
oper expens
non- adjust
research develop
gener administr
sale
research develop
gener administr
proce issuanc redeem convert convert prefer stock net issuanc cost
proce issuanc common stock upon exercis stock option
proce sale restrict common stock
payment debt issuanc cost
proce borrow loan secur agreement
net cash provid financ activ
net decreas increas cash cash equival
cash equival begin period
cash equival end period
adjust reconcil net loss net cash use oper activ
depreci amort
issuanc common stock technolog licens
chang fair valu prefer stock warrant liabil
accret discount market secur
loss dispos properti equip
chang oper asset liabil
prepaid expens current asset
accru expens current liabil
net cash use oper activ
purchas properti equip
purchas market secur
net cash use invest activ
brexanolon launch primari valuat
brexanolon launch primari valuat
brexanolon approv asset
global peak sale potenti
clear unmet need form basi
valuat clear upsid
derisk data mdd
potenti much broader profil
insomnia parkinson diseas addit
indic multi-billon dollar
pipelin broad continu offer
new drug extens effort target
gaba nmda
brexanolon launch steep trajectori provid
bulk valuat strong launch mdd bipolar
insomnia
brexanolon key near-term driver
launch howev form
bulk valuat
brexanolon launch provid bulk valuat
launch mdd bipoloar insomnia
approv mdd bipolar insomnia
launch modest
neg safeti efficaci data
therapeut program
unexpect delay clinic
potenti intellectu properti
challeng could impact futur revenu
long-term prospect sarepta dmd franchis drive valu
long-term prospect sarepta dmd franchis
pt deriv dcf use discount rate
termin growth beyond valu sarepta dmd franchis
bull scenario assum exondi achiev rapid launch sale
taper peak penetr achiev also assum aggress sale
exon approv well signific updat gene therapi
base case scenario assum continu strength exondi well
eventu approv golodirsen camisersen risk-adjust
dmd gene therapi total revenu
assum lower peak penetr exondi approv golodirsen
modest sale approv camisersen downstream eros usag
includ revenu altern mutat
overweight thesi base
strong initi dmd genetherapi data
manag abil captur signific
market share dmd gene therapi
product gene therapi remain riski
believ initi data derisk program
provid signific upsid potenti
base busi exon skip drug
pipelin larg divers offer lgmd
potenti upsid driver
time market clinic success
risk achiev price
updat dmd gene therapi
program includ risk relat
manufactur on-going regulatori
failur secur addit regulatori
approv obtain reimburs could
data competitor compani could
either posit neg impact
sarepta posit dmd market
assum entinostat achiev rapid uptak hr bc uptak
combin i/o therapi nsclc melanoma also assum
combin hormon therapi hr breast cancer exce base case
expect incorpor project risk adjust i/o combin
sale hr her- sale
assum bulk valu come entinostat combin i/o
therapi howev valuat base lower sale project
risk adjust i/o assum modest hr her- breast cancer sale
project risk adjust
assum entinostat fail achiev suffici clinic result either hr
her- breast cancer i/o combin studi
equal-weight syndax
develop class hdac entinostat
near-term compani stock
leverag outcom phiii
trial hr breast cancer although
menin-llr program intrigu
confid entinostat/checkpoint
inhibitor combin wane somewhat
howev could eventu path
forward inflam tumor nsclc
melanoma
stock valuat highli link
success phiii trial
risk achiev price
neg safeti efficaci data
therapeut program
unexpect challeng checkpoint
inhibitor i/o therapi gener
could dampen syndax opportun
potenti intellectu properti
challeng could impact futur revenu
crysvita drive risk/reward
crysvita
pt deriv dcf use discount
rate model peak risk-adjust revenu addit
peak ww sale mepsevii crysvita
model peak unadjust ww sale
adjust
use probabl success po
posit data readout better-than-expect launch assum higher
po po follow subsequ
confirm posit data cohort cohort respect
support advanc program phase addit assum
better-than-expect launch lead greater peak market share
crysvita mepsevii
strong crysvita launch base case assumpt describ price
target methodolog
pipelin product fail bear case assum fail
approv call question mepsevii crysvita face
slower adopt us
overweight rate base
belief street undervalu
crysvita launch remain strong
potenti upsid greater adopt
adult famili
data promis
confid program
like ultragenyx third
compani continu deepen
diversifi pipelin new gene therapi
mrna candid
updat phase cohort
clariti ema potenti
file lc-faod phase data
risk achiev price
crysvita mepsevii may face
commercial/reimburs challeng
achiev suffici patient adopt
data subsequ indic
pipelin candid may succeed
even data posit fda may
probabl success anti-ag market well osteoarthr knee
probabl success anti-ag market well osteoarthr knee
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model osteoarthr oa addit
success oa drive peak ww sale probabl
success coupl probabl success penetr anti-ag
market broadli
success oa drive peak ww sale probabl
success coupl probabl success penetr anti-ag
market broadli remain bull case
program fail valu compani cash
manag pioneer novel
biolog senesc cell
opportun deliv step-funct chang
treatment chronic diseas
preclin model support
impact sasp factor senesc
suggest benefit
remov senesc cell
oa offer proof-of-concept model
clear biomark clinic endpoint
follow-up long-term chronic data
addit ind file follow-up
product includ eye
risk achiev price
biolog approach
novel initi program fail falter
investor like heavili discount
competit space
privat
initi oa program may right
target test senesc cell snc
follow-up period dose period
medicin may long enough
kinet remov snc see
therapeut respons known
adjust reconcil net loss net cash use oper activ
depreci amort
loss sale equip
amort premium discount market secur
loss extinguish promissori note
common stock grant third parti
accret tenant improv allow
chang oper asset liabil
prepain expens current asset
accru liabil current liabil
defer rent net current portion
net cash use oper activ
purchas market secur
matur market secur
purchas cost method invest
purchas properti equip
net cash use incest activ
proce fom issuanc convert promissori note payabl
proce issuanc convert prefr stock net
proce issuanc common stock upon exercis stock option net
payment made capit leas oblig
net cash provid financ activ
chang
begin year
 restrict end year
market secur end year
oper
base case forecast deriv explicit forecast
bcma actr product discount
termin growth rate dcf model
better efficaci safeti signal solid tumor model peak sale
liquid tumor bcma myeloma posit initi data
allow us valu solid tumor opportun implicitli
higher termin valu
activ product use refractori
patient take share current approv car-t base
cleaner safeti profil model peak sale includ
base valu program fail
overweight unum base
view technolog could provid
robust therapeut window compar
especi solid tumor
believ manag outlin
reason strategi deal toxic
encount initi phi studi
addit data rituximab
sea-bcma
initi solid tumor data
safeti updat trastuzumab
solid tumor studi
updat data rituximab
nhl studi
data sea-bcma multipl
myeloma studi
risk achiev price
safeti issu compromis actr
lack clean safeti efficaci
lack differenti
activ
cost expens
product revenues/royalti
loss discontinu oper net tax
loss sale discontinu oper net tax
net loss comprehens loss
oper expens
oper expens
equival
prepaid expens current asset
properti equip net
defer revenu net current portion
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
chang oper asset liabil
pre-paid expens asset
accru expens liabil
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas market secur
sale matur market secur
net use invest activ
flow financ activ
proce exercis stock option equiti
proce issuanc common stock
chang equival
equival begin year
equival end year
market secur end year
triplet approv
triplet approv uptak life-cycl manag oper margin drive
uptak life-cycl manag oper margin drive
ww penetr across cf medicin life-cycl extens extend
franchis bull case assum higher penetr tripl
therapi het/min homozygot patient initi tripl data
replic phiii therapi launch ww sale
cf aatd us eu commerci success key
risk-adjust tripl combo success mainten key cf franchis
life-cycl extens base case assum penetr tripl
combin homozygot heterozygot risk-adjust peak ww
sale cf aatd
modest orkambi uptak tripl combin fail achiev approv
het/min popul bear case assum row us
penetr orkambi homozyg cf patient total peak ww sale
cf aatd therapi peak
overweight vertex believ
initi tripl data replic phiii
studi see vertex clear leader
cf therapi believ manag
potenti deliv ep
initi phi phii data tripl
het/min popul better
kalydeco-lin efficaci
homozyg popul thu includ
risk-adjust tripl combin revenu
base case
efficaci data aatd mice model
suggest efficaci corrector human
therefor model includ risk-
adjust revenu corrector
believ potenti
competit believ vertex
signific advantag posit
on-market doubl combin in-
share competitor long-
main driver vertex phiii
tripl studi time approv launch
uptak current therapi
orkambi/kalydeco uptak in-
develop therapi tez/iva triplet
risk achiev price
combo penetr fall short
kalydeco sale fail meet
data clinic candid tripl
combin fail meet expect
data competit exce
clinic trial nda file
adjust reconcil net loss net cash use oper activ
depreci amort expens
chang oper asset liabil
prepaid expens asset
accru expens liabil
net cash use oper activ
purchas market secur
sale matur market secur
payment acquisit variabl interest entiti
expenditur properti equip
increas decreas asset
net cash use invest activ
issuanc common stock benefit plan
payment redeem secur note
payment capit leas oblig
proce senior secur term loan
proce revolv credit facil
tax benefit stock option
net cash provid financ activ
effect exchang rate chang cash cash equival
net decreas increas cash cash equival
cash equival begin period
cash equival end period
equal-weight rate base limit
clinic catalyst
major valuat driven
vy-aadc parkinson
vy-aadc phase data
vy-aadc phase data
risk achiev price
enrol faster expect addit vy-
aadc data increas investor confid
program expect
earli stage candid advanc
clinic vy-aadc pivot studi
enrol expect safeti concern aris
longer term data reflect strong
durabl respons
vy-aadc parkinson drive risk/reward
vy-aadc parkinson drive risk/reward
pt deriv dcf use discount
rate model unadjust ww vy-aadc revenu
voyag receiv profit share us low- high-
teen royalti eu sale risk-adjust use po vy-
huntington model peak unadjust ww sale
adjust use po
optimist view vy-aadc scenario assum po
follow strong long-term data greater market share vy-aadc us
eu
vy-aadc us launch base case assumpt describ
price target methodolog
gene therapi platform fail bear case assum voyag unabl
advanc product candid trade cash value-per-share
dasiglucagon glepaglutid driver
dasiglucagon glepaglutid driver
pt deriv dcf use discount rate
glepaglutid dasiglucagon demonstr superior profil product
differenti sb hypoglycemia respect lead acceler
uptak versu current standard care
dasiglucagon glepaglutid competit pipelin asset
approv view competit standard care
late state pipelin falter dasiglucagon glepaglutid fail reach
strong pipelin support ow rate
view zealand strong pipelin
led two therapi glepaglutid
dasiglucagon improv version
standard care drug
dasiglucagon could better offer
dasiglucagon rescu medic
sever hypoglycemia repres
conveni offer current market
glucagon like drive strong uptak
therapi approv potenti futur use
artifici pancrea system orphan
repres upsid estim
glepaglutid next-gen
could improv profil teduglutid
earlier featur short half
life requir complex multi-step
reconstitut process prior administr
glepaglutid enhanc stabil
extend half life allow drug
glepaglutid dasiglucagon success
risk achiev price
fail clinic trial pipelin candid
dasiglucagon glepaglutid
potenti need rais dilut equiti
